Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS
Among Human immunodeficiency virus (HIV) infected individuals, around two-thirds of patients present with neuroAIDS, where HIV-associated neurocognitive disorders (HAND), and HIV-associated dementia (HAD) are the most prevailing neurological complications. The neuropathology of neuroAIDS can be char...
Main Authors: | Kumar Swatantra, Maurya Vimal K, Dandu Himanshu R, Bhatt Madan LB, Saxena Shailendra K |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2018-05-01
|
Series: | Biomolecular Concepts |
Subjects: | |
Online Access: | https://doi.org/10.1515/bmc-2018-0005 |
Similar Items
-
Contribution of CNS cells in NeuroAIDS
by: Ashish Swarup Verma, et al.
Published: (2010-01-01) -
NeuroAid II (MLC901) in Haemorrhagic Stroke
by: Chai-Hoon Nowel Tan, et al.
Published: (2020-12-01) -
Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS
by: Anupam Sarma, et al.
Published: (2020-12-01) -
Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS
by: Sonia Moretti, et al.
Published: (2021-08-01) -
Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats
by: Katayoun Heshmatzad, et al.
Published: (2021-04-01)